Organic Active Ingredients TRIZ Cases

A low-pH liposomal Centella and AHA emulsion reduces senescent skin cells, inflammation, and fibroblast decline in dermatoporosis.

Direct 5-HT2A receptor binding by indoline compounds aims to treat psychosis and CNS disorders without hallucinogenic effects.

A segmented 5'-UTR, ORF, and 3'-UTR design improves mRNA stability, translation efficiency, and vaccine immunogenicity.

Fluorinated aryl hydantoin compounds extend half-life, target juvenile schistosomula, and reduce antiandrogenic effects in schistosomiasis treatment.

Combining resin-bound immediate and barrier-coated release phases gives amphetamine tablets fast onset and a stable 13-hour effect, even when chewed.

Novel TRPV2 blockers selectively inhibit tumor and inflammatory TRPV2 activity while minimizing healthy-cell cytotoxicity.

Phosphate esterification makes budesonide water-soluble and stable, enabling uniform nebulizer formulations without deposition or additives.

Adding a volatile solvent lowers in-situ gel viscosity for filtration sterilization, then solvent removal cuts degradation and impurities.

Selecting mesenchymal stem cells with high HLA-A2 expression suppresses TNF-α and boosts CD163 and Arg-1 for inflammatory disease treatment.

Connexin and NLRP3 inflammasome modulators target inflammation and cellular signaling to relieve long COVID and related post-acute symptoms.

A calcium phosphate putty uses iron excipients for visible mixing, X-ray contrast, controlled agent delivery, and safer bone defect repair.

A 9β,10α neurosteroid prolongs GABA-activated chloride channel opening to improve CNS disorder treatment with better stability and fewer side effects.

Selective p38 MAPK inhibition lowers severe influenza cytokine release while preserving protective immune response and limiting respiratory complications.

Targeting autotaxin with a modified aptamer suppresses RPE proliferation and migration to help prevent proliferative vitreoretinopathy.

Region-specific GI sampling guides antimicrobial susceptibility testing and targeted delivery for personalized SIBO treatment.

Crushed cartridge emulsion is released through microneedles, using heat or ultrasound to improve dermal absorption while minimizing skin irritation.

Combining core and outer nicotine formulations enables fast and extended release with varied organoleptic properties in one dosage form.

EDTA and a sulfated polysaccharide stabilize isoproterenol in microneedle coatings, enabling higher drug loading during production and storage.

Cyclodextrin and non-sulphonic acid keep gedatolisib in a clear, particle-free aqueous solution for therapeutic intravenous dosing.

Polymer-linked SN22 uses labile ester bonds to sustain intratumoral drug levels in neuroblastoma while limiting systemic toxicity.

Targeting HIF-1α with fursultiamine suppresses choroidal neovascularization and vascular leakage while avoiding frequent anti-VEGF injections.

Targeting KDM1A with vafidemstat addresses non-aggressive borderline personality disorder symptoms while avoiding the side effects of off-label drugs.

By targeting TGR5 to trigger GLP-1 secretion, cholic acid 7-sulfate derivatives improve glucose tolerance and insulin sensitivity.

Adding hydroxycitric acid during T cell culture improves persistence, antitumor activity, and survival while reducing apoptosis.

A single formulation combining beta-blocker, sartan, and optional diuretic improves blood pressure control while reducing regimen complexity and side effects.

A single intravitreal rAAV2 dose enables sustained aflibercept expression, reducing repeat anti-VEGF injections and related eye complications.

Sequential channel mixing forms uniform lipid nanoparticles without sorting while lowering ionizable lipid content and toxicity risk.

Hot-melt extruded posaconazole granules with enteric polymers stabilize dissolution and improve bioavailability with less food effect.

Genetic detection of mutant SPOP guides AKT plus BET inhibitor therapy to resensitize resistant cancers, including prostate cancer.

Electrospinning decellularized ECM with a temporary synthetic polymer yields reproducible, biocompatible scaffolds with native-like structure.

Ascorbyl palmitate is added to methylphenidate formulations to intercept nitrosation and reduce carcinogenic nitrosamine formation.

Small-molecule 4-alkoxybenzimidazole compounds maintain GLP-1 agonist activity while enabling oral dosing instead of peptide injection.

A 4-bromobutyric acid linker enables a highly pure HA-paclitaxel conjugate while avoiding Cremophor EL reactions and dialysis.

Low molecular weight ferroportin-inhibitor salts help prevent iron transport, improving stability and reducing toxicity in iron overload treatment.

A spring-driven bi-dose nasal spray delivers two equal midazolam doses in any patient position without priming, improving hygiene and dosing accuracy.

An oral HD tablet combines Compound 1 with excipients to reduce HTT mRNA and protein while slowing motor, cognitive, and psychiatric decline.

A three-step exatecan route uses mild acid-catalyzed inversion and cyclization to raise yield, simplify isomer control, and cut scale-up cost.

GalNAc-conjugated PD-L1 siRNA improves liver-specific delivery and mRNA inhibition while reducing systemic side effects and extending dosing intervals.

Biased MC4R agonists restore impaired NFAT signaling in deficiency-linked obesity, enabling treatment selection for like-wild-type mutations.

Novel Formula I capsid inhibitor compounds target drug-resistant HIV while improving stability and pharmacokinetic profiles.

A mixed organic acid feed additive lowers viral load in contaminated animal feed and helps reduce infection risk and clinical symptoms.

Patient monitoring and machine learning reshape non-linear opioid tapering plans to address withdrawal, anxiety, and side effects.

A palladium-catalyzed route to Compound IX raises yield and purity while using commercially available starting materials to lower synthesis cost.

An oral composition of a cereblon-binding compound improves multiple myeloma response while reducing toxicity and supporting stable formulation.

Co-administering polymyxins with aminoglycosides in a dry powder inhaler reduces lung toxicity while improving aerosolization for respiratory infections.

A stable pyridinylphenyl crystal form complexes with aldehydes, penetrates the cornea, and reduces dry eye inflammation and toxicity.

Biomarker shifts after treatment help predict cancer therapy sensitivity early, avoiding months of waiting for clinical response assessment.

Formula I compounds selectively inhibit TYK2 to treat inflammatory disorders while limiting side effects from broader JAK inhibition.

An oxygen-carrying perfusion composition uses erythrocruorin and folate/BH4 micronutrients to limit ischemic damage and reperfusion injury.

NTRK/ALK/ROS1 inhibitors combined with venetoclax restore apoptosis in resistant AML linked to low TP53 expression or TP53 mutation.